Johan Juhlin, CEO & Co-Founder, Mavatar Johan Juhlin is a seasoned entrepreneur and healthcare innovator with over 25 years of experience in the medical field, including senior leadership roles in major pharmaceutical companies. As the former Commercial Director at Ventana Medical Inc., he played a pivotal role in the global launch of the HER2 marker for breast cancer in 1998. Under his leadership, the marker achieved rapid adoption—used by 12% of patients in its first year and reaching an impressive 94% penetration within two years. By 2020, HER2 had grown into a $10.4 billion market. Now, as the CEO and co-founder of Mavatar, Juhlin is driving a new era of AI-powered precision medicine. Mavatar is redefining the future of healthcare by leveraging medical avatars and artificial intelligence to accelerate drug development, optimize clinical trials, and deliver hyper-personalized treatment plans. With his proven track record of scaling groundbreaking medical innovations, Juhlin is poised to lead Mavatar toward transforming patient care on a global scale.